SYK: Leadership change · Company disclosure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, the Board of Directors of Stryker Corporation (the “Company”) increased the number of authorized directors from 11 to 12 and elected James E. Davis to fill the resulting vacancy. Mr. Davis’s election will become effective on January 1, 2027, and he has not been appointed to any committee of the Board at this time. Mr. Davis has been CEO and President of Quest Diagnostics (“Quest”) since November 2022 and assumed the role of Chairman of the Quest Board in April 2023. Mr. Davis joined Quest in 2013 as Senior Vice President, Diagnostic Services and was named Senior Vice President, Operations in February 2014. Before joining Quest, he served as CEO of InSightec, Inc., a global medical device company. Prior to that, Mr. Davis spent two decades in senior management roles across General Electric’s healthcare and aviation businesses, including five years leading General Electric’s MRI business. Before General Electric, Mr. Davis led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc. Mr. Davis will be compensated for his services consistent with the Company’s other non-employee directors, as described in the Company’s proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2026. In connection with his election to the Company’s Board of Directors, the Company will enter into the form of indemnification agreement for directors, a copy of which is filed as Exhibit 10(xxviii) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on Feb